Zimmer Biomet Holdings, Inc. Announces Quarterly Dividend of $0.24 (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBHGet Free Report) announced a quarterly dividend on Wednesday, December 18th,RTT News reports. Shareholders of record on Monday, December 30th will be given a dividend of 0.24 per share by the medical equipment provider on Friday, January 31st. This represents a $0.96 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend is Monday, December 30th.

Zimmer Biomet has a payout ratio of 11.2% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Zimmer Biomet to earn $8.58 per share next year, which means the company should continue to be able to cover its $0.96 annual dividend with an expected future payout ratio of 11.2%.

Zimmer Biomet Trading Down 0.0 %

NYSE:ZBH opened at $105.81 on Friday. Zimmer Biomet has a 12 month low of $101.47 and a 12 month high of $133.90. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The company has a 50-day moving average price of $108.01 and a 200-day moving average price of $108.51. The stock has a market cap of $21.06 billion, a price-to-earnings ratio of 20.12, a P/E/G ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBHGet Free Report) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.65 EPS. Equities analysts predict that Zimmer Biomet will post 7.99 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ZBH shares. BTIG Research reduced their price target on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. Wells Fargo & Company raised their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. TD Cowen lowered their price objective on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a research report on Friday, September 6th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $125.00 to $128.00 in a research note on Tuesday. Finally, Raymond James reduced their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a report on Monday, October 14th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $123.33.

View Our Latest Stock Analysis on Zimmer Biomet

About Zimmer Biomet

(Get Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Further Reading

Dividend History for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.